Immuneering (NASDAQ:IMRX) Sees Strong Trading Volume – Still a Buy?

Shares of Immuneering Corporation (NASDAQ:IMRX) saw unusually-strong trading volume on Wednesday . Approximately 1,529,284 shares traded hands during trading, an increase of 43% from the previous session’s volume of 1,067,995 shares.The stock last traded at $7.9140 and had previously closed at $6.72.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IMRX. Oppenheimer upped their price objective on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. Leerink Partners assumed coverage on Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 price target for the company. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Needham & Company LLC upped their price objective on shares of Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immuneering has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Price Performance

The stock has a market capitalization of $522.37 million, a P/E ratio of -4.54 and a beta of 0.48. The stock has a fifty day moving average price of $6.62 and a 200 day moving average price of $5.72.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Several hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new stake in Immuneering in the 3rd quarter worth approximately $717,000. CIBC Private Wealth Group LLC grew its position in shares of Immuneering by 233.7% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 50,051 shares of the company’s stock valued at $350,000 after purchasing an additional 35,051 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Immuneering in the third quarter worth $350,000. Heights Capital Management Inc. bought a new stake in Immuneering during the third quarter valued at $140,000. Finally, Woodline Partners LP purchased a new stake in shares of Immuneering in the 3rd quarter valued at about $1,050,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.